ZURA Stock Forecast 2025-2026
Distance to ZURA Price Targets
ZURA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Zura Bio (ZURA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ZURA and similar high-potential opportunities.
Latest ZURA Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, ZURA has a bullish consensus with a median price target of $12.00 (ranging from $5.00 to $26.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $1.49, the median forecast implies a 705.4% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 1,645.0% upside. Conversely, the most conservative target is provided by Mitchell Kapoor at HC Wainwright & Co., suggesting a 235.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZURA Analyst Ratings
ZURA Price Target Range
Latest ZURA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZURA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 24, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $5.00 |
| Dec 11, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $0.00 | |
| Nov 18, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $5.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $5.00 |
| Nov 9, 2024 | Chardan Capital | Buy | Maintains | $0.00 | |
| Nov 8, 2024 | Chardan Capital | Matthew Barcus | Buy | Maintains | $12.00 |
| Nov 4, 2024 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $15.00 |
| Oct 21, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $5.00 |
| Oct 18, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $0.00 |
| Sep 19, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $26.00 |
| Sep 5, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Initiates | $5.00 |
| Aug 15, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $0.00 |
| Jun 17, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $0.00 |
| Jun 12, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Initiates | $0.00 |
| May 10, 2024 | Oppenheimer | Jeff Jones | Outperform | Maintains | $21.00 |
| May 3, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Initiates | $26.00 |
| Apr 1, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $16.00 |
| Oct 10, 2023 | Ladenburg Thalmann | Aydin Huseynov | Buy | Initiates | $10.00 |
| Aug 25, 2023 | Oppenheimer | Justin Kim | Outperform | Initiates | $17.00 |
| Aug 15, 2023 | Raymond James | Steven Seedhouse | Strong Buy | Maintains | $22.00 |
Zura Bio Ltd. (ZURA) Competitors
The following stocks are similar to Zura Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zura Bio Ltd. (ZURA) Financial Data
Zura Bio Ltd. has a market capitalization of $88.15M with a P/E ratio of 7.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -36.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Zura Bio Ltd. (ZURA) Business Model
About Zura Bio Ltd.
Develops innovative therapeutics for immune disorders.
Zura Bio Ltd. focuses on creating pioneering drugs and treatment protocols for immune disorders and other diseases. The company generates revenue through the development and commercialization of its therapeutics, targeting unmet medical needs in the pharmaceutical and healthcare sectors.
Zura Bio is positioned in the growing biopharma market, attracting investor interest due to its potential for groundbreaking advancements. Its innovations may also impact healthcare equipment and supply chain management, as new treatments can increase demand for related medical services and products.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Mr. Robert Lisicki
Country
United States
IPO Year
2023
Website
zurabio.comZura Bio Ltd. (ZURA) Latest News & Analysis
Zura Bio Limited (Nasdaq: ZURA) will participate in the Leerink Partners Global Healthcare Conference on March 11, 2025, at 1:40 p.m. ET, with a live webcast available.
Zura Bio's participation in a major healthcare conference and investor meetings signals potential growth opportunities and insights into their drug development progress, impacting stock performance.
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)
2 months agoZura Bio Limited (ZURA) is technically oversold, suggesting reduced selling pressure. Analysts are revising earnings estimates higher, indicating a potential trend reversal.
Zura Bio Limited's oversold status and rising earnings estimates suggest reduced selling pressure and a possible stock price recovery, signaling a favorable investment opportunity.
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
3 months agoZura Bio has launched TibuSURE, a Phase 2 global study to evaluate tibulizumab for treating systemic sclerosis in adults.
Zura Bio's Phase 2 study of tibulizumab for systemic sclerosis could lead to significant advancements in treatment, potentially impacting future revenue and stock performance.
Zura Bio Limited (Nasdaq: ZURA) will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 3, 2024, and host investor meetings in New York.
Zura Bio's participation in a major healthcare conference highlights its visibility and potential to attract investor interest, signaling developments in its clinical-stage pipeline.
Zura Bio Limited (Nasdaq: ZURA) submitted a protocol to the FDA for a Phase 2 study on tibulizumab, a dual-pathway antibody for treating autoimmune and inflammatory diseases.
Zura Bio's IND submission for a Phase 2 study of tibulizumab could signal significant progress in drug development, potentially affecting stock performance and market perception of the company.
Zura Bio Limited (Nasdaq: ZURA) reported Q3 2024 financial results, highlighting progress on initiating a Phase 2 trial for tibulizumab in systemic sclerosis (SSc).
Zura Bio's progress in initiating a Phase 2 trial for tibulizumab signals potential advancements in immunology treatments, impacting its market valuation and future revenue prospects.
Frequently Asked Questions About ZURA Stock
What is Zura Bio Ltd.'s (ZURA) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Zura Bio Ltd. (ZURA) has a median price target of $12.00. The highest price target is $26.00 and the lowest is $5.00.
Is ZURA stock a good investment in 2025?
According to current analyst ratings, ZURA has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.49. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZURA stock?
Wall Street analysts predict ZURA stock could reach $12.00 in the next 12 months. This represents a 705.4% increase from the current price of $1.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zura Bio Ltd.'s business model?
Zura Bio Ltd. focuses on creating pioneering drugs and treatment protocols for immune disorders and other diseases. The company generates revenue through the development and commercialization of its therapeutics, targeting unmet medical needs in the pharmaceutical and healthcare sectors.
What is the highest forecasted price for ZURA Zura Bio Ltd.?
The highest price target for ZURA is $26.00 from Yasmeen Rahimi at Piper Sandler, which represents a 1,645.0% increase from the current price of $1.49.
What is the lowest forecasted price for ZURA Zura Bio Ltd.?
The lowest price target for ZURA is $5.00 from Mitchell Kapoor at HC Wainwright & Co., which represents a 235.6% increase from the current price of $1.49.
What is the overall ZURA consensus from analysts for Zura Bio Ltd.?
The overall analyst consensus for ZURA is bullish. Out of 11 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are ZURA stock price projections?
Stock price projections, including those for Zura Bio Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
